They did not comment on efficacy within the subtypes; logic would say that with ADP being 67% of enrollees, there must have been stat sig efficacy there for sure to get an early stop; on the others, my logic would say that PDD and DLB likely saw stat sig efficacy as there is previous PhIII success in PDP; the others no way to tell, but the others are <15% of the indication.

 

An observation that just came to me when looking at those epidemiology %'s:

Looks like the relative prevalence of PDP v DLB has changed!  It used to be the DLB market was larger than PDP (they differ only in onset of symtpoms: if motor symptoms first, then PDP, if dementia symtpoms first, then DLB).  Seems that only one of those indications being approved for Nup use has changed diagnosing habits:) 

 

Sort of off-label being made to become on-label by stroke of the pen.  Well done to the diagnosing MDs.